INTRODUCTION {#s1}
============

Thyroid cancer has been rising rapidly in recent decades \[[@R1]--[@R5]\]. Papillary thyroid cancer (PTC) accounts for 80--90% of all thyroid malignancies, making it the most common type of thyroid malignancy \[[@R6]\]. Rare histological variants of PTC include follicular, tall cell, columnar cell, diffuse sclerosing, solid, hobnail, and insular variants \[[@R7]--[@R11]\].

The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) is the largest publicly available data source for cancer incidence and survival in the United States \[[@R12], [@R13]\]. Propensity score matching (PSM) method is a statistical matching technique for analyzing observational data by estimating the effects of a treatment, policy, or other intervention and accounting for covariates that predict receiving the treatment. PSM attempts to reduce the bias due to confounding variables.

Hürthle cell tumors in thyroid neoplasms include adenomas, carcinomas, and papillary thyroid carcinomas \[i.e., oxyphilic cell papillary thyroid carcinoma (OCPTC)\]. Hürthle cell carcinoma a rare variant of PTC and considered an uncommon and more aggressive thyroid cancer by many researchers \[[@R14], [@R15]\]. However, there is still a lack of research about OCPTC, especially in large populations. In this study, we investigated the prognosis of OCPTC on the basis of reliable and large-scale research dataset from the SEER database 2004--2013 using PSM methods.

RESULTS {#s2}
=======

Demographic and clinical features {#s2_1}
---------------------------------

A total of 66305 patients with different histological subtypes \[n = 147, OCPTC; n = 60739, classic papillary thyroid cancer (CPTC); and n = 5419, follicular thyroid cancer (FTC)\] were included in this study. The study patients' mean age and survival in months for the different histological subtype stages are shown in Table [1](#T1){ref-type="table"}. Patients with OCPTC had significantly shorter months of survival than patients with other stages.

###### Characteristics for Patients with different histological types

  Covariate                level                                  Histological types                                              
  ------------------------ -------------------------------------- -------------------- -------------- ------------- ------------- ---------
  Age (year)                                                      52.22±16.46          48.36±15.35    0.001         50.79±17.29   0.253
  Sex                      Female                                 109(74.1%)           46786(77.0%)   0.407         3843(70.9%)   0.394
                           Male                                   38(25.9%)            13953(23.0%)   1576(29.1%)                 
  Race                     White                                  131(90.3%)           49651(82.8%)   0.056         4186(78.3%)   0.001
                           Black                                  4(2.8%)              3159(5.3%)     640(12.0%)                  
                           Other                                  10(6.9%)             7133(11.9%)    517(9.7%)                   
  T stage                  T1                                     77(52.7%)            37974(63.8%)   0.001         1240(23.7%)   \<0.001
                           T2                                     35(24.0%)            8062(13.6%)    2110(40.4%)                 
                           T3                                     31(21.2%)            10845(18.2%)   1682(32.2%)                 
                           T4                                     3(2.1%)              2599(4.4%)     191(3.7%)                   
  N-stage                  N0                                     118(82.5%)           44102(74.9%)   0.001         5114(96.9%)   \<0.001
                           N1                                     25(17.5%)            14744(25.1%)   161(3.1%)                   
  M-stage                  M0                                     144(%)               59951(%)       0.427         5093(%)       0.044
                           M1                                     3(%)                 788(%)         326(%)                      
  Multifocality            No                                     87(62.1%)            35549(60.1%)   0.624         4464(85.7%)   \<0.001
                           Yes                                    53(37.9%)            23591(39.9%)   742(14.3%)                  
  Extension                No                                     121(82.3%)           49129(82.1%)   0.935         4795(90.4%)   0.001
                           Yes                                    26(17.7%)            10744(17.9%)   512(9.6%)                   
  Radiation                None or refused                        70(48.6%)            30701(51.7%)   0.112         2303(43.6%)   0.309
                           External beamradiation therapy         6(4.2%)              1105(1.9%)     163(43.6%)                  
                           Radioactive I-131 ablation             68(47.2%)            27548(46.4%)   2822(53.4%)                 
  Surgery                  Biopsy                                 1(0.7%)              1513(2.5%)     0.432         183(3.4%)     0.317
                           Lobectomy                              20(13.9%)            7750(12.9%)    1207(22.5%)                 
                           Subtotal or near-total thyroidectomy   7(4.9%)              2116(3.5%)     277(5.2%)                   
                           Total thyroidectomy                    116(80.6%)           48771(81.1%)   5363(68.9%)                 
  Survival months(month)                                          43.59±33.60          48.98±33.40    0.038         52.67±33.48   0.001

OCPTC: oxyphilic cell papillary thyroid carcinoma; CPTC: classic papillary thyroid cancer; FTC: follicular thyroid carcinoma;

Cancer-specific and all-cause mortality rates for different histological subtypes {#s2_2}
---------------------------------------------------------------------------------

In the study cohort, the cancer-specific mortality rate, per 1000 person-years, for OCPTC, CPTC, and FTC were 1.872 \[95% confidence interval (CI), 0.264--13.293\], 2.512 (95% CI, 2.323--2.718), and 6.68 (95% CI, 5.722--7.809), respectively (Table [2](#T2){ref-type="table"}). The all-cause mortality, per 1000 person-years, in patients with OCPTC, CPTC, and FTC were 16.852 (95% CI, 8.769--32.389), 10.538 (95% CI, 10.141--10.950) and 18.583 (95% CI, 16.929--20.399), respectively (Table [2](#T2){ref-type="table"}).

###### Hazard Ratios of different histological types for the cancer specific deaths and all cause deaths of thyroid cancer

  Histological types   Cancer-Specific Deaths,   \%     Cancer-Specific Deaths per   95% CI         All Cause Deaths,   \%     All Cause Deaths per   95% CI
  -------------------- ------------------------- ------ ---------------------------- -------------- ------------------- ------ ---------------------- ---------------
  OXPTC                1                         0.68   1.872                        0.264-13.293   9                   6.12   16.852                 8.769-32.389
  CPTC                 659                       1.08   2.512                        2.323-2.718    2722                4.48   10.538                 10.141-10.950
  FTC                  178                       3.28   6.685                        5.722-7.809    474                 8.75   18.583                 16.929-20.399

OXPTC: oxyphilic cell papillary thyroid carcinoma; CPTC: classic papillary thyroid cancer; FTC: follicular thyroid carcinoma;

Risk factors for thyroid cancer-specific and all-cause mortality rates {#s2_3}
----------------------------------------------------------------------

According to the univariate Cox regression analyses, age, sex, race, T/N/M stage, extension, radiation treatment, and surgical approach were significant risk factors of cancer-specific mortality. In the multivariate Cox regression model, CPTC and FTC showed no significant risk for cancer-specific mortality compared to OCPTC after adjusting for influential risk factors (Table [3](#T3){ref-type="table"}). In the univariate Cox regression analyses, age, sex, race, TNM stage, multifocality, radiation, and surgical approach were found to be significant risk factors for all-cause mortality. In the multivariate Cox regression analysis, OCPTC showed no significant risk for all-cause mortality compared to CPTC and FTC (Table [3](#T3){ref-type="table"}).

###### Risk factors for survival: outcome of thyroid cancer specific Mortality and all-cause mortality

  Covariate            level                                                Thyroid Cancer specific mortality   All cause mortality                                                                                           
  -------------------- ---------------------------------------------------- ----------------------------------- --------------------- ---------------------- --------- ----------------------- --------- -------------------- ---------
  Age                                                                       1.098(1.092-1.103)                  \<0.001               1.063(1.057-1.070)     \<0.001   1.087(1.084-1.089)      \<0.001   1.072(1.069-1.075)   \<0.001
  Sex                  Female                                               ref                                                       ref                              ref                               ref                  
                       Male                                                 2.630(2.295-3.014)                  \<0.001               1.117(0.939-1.328)     0.212     2.422(2.258-2.597)      \<0.001   1.580(1.485-1.713)   \<0.001
  Race                 White                                                ref                                                       ref                              ref                               ref                  
                       Black                                                1.157(0.874-1.530)                  0.308                 1.018(0.699-1.483)     0.925     1.334(1.170-1.521)      \<0.001   1.255(1.078-1.462)   0.003
                       Other                                                1.412(1.168-1.708)                  \<0.001               0.951(0.749-1.207)     0.678     0.929(0.828-1.042)      0.206     0.791(0.692-0.905)   0.001
  histological types   OXPTC                                                ref                                                       ref                              ref                               ref                  
                       CPTC                                                 1.480(0.208-10.520)                 0.695                 0.747(0.105-5.332)     0.771     0.659(0.343-1.269)      0.212     0.744(0.334-1.659)   0.470
                       FTC                                                  4.289(0.601-30.615)                 0.147                 1.184(0.164-8.529)     0.867     1.206(0.623-2.331)      0.578     0.893(0.397-2.005)   0.783
  T-stage              T1                                                   ref                                                       ref                              ref                               ref                  
                       T2                                                   3.362(2.380-4.750)                  \<0.001               2.830(1.950-4.105)     \<0.001   1.128(1.006-1.265)      0.039     1.167(1.030-1.323)   0.015
                       T3                                                   8.863(6.717-11.693)                 \<0.001               4.111(2.742-6.163)     \<0.001   1.677(1.526-1.843)      \<0.001   1.246(1.061-1.463)   0.007
                       T4                                                   91.998(71.220-118.838)              \<0.001               14.248(8.974-22.622)   \<0.001   8.020(7.306-8.804)      \<0.001   2.589(2.090-3.208)   \<0.001
  N stage              N0                                                   ref                                                       ref                              ref                               ref                  
                       N1                                                   4.326(3.735-5.012)                  \<0.001               1.961(1.612-2.385)     \<0.001   1.649(1.525-1.782)      \<0.001   1.451(1.309-1.609)   \<0.001
  M-stage              M0                                                   ref                                                       ref                              ref                               ref                  
                       M1                                                   50.426(43.883-57.943)               \<0.001               5.897(4.785-7.268)     \<0.001   15.305(13.911-16.838)   \<0.001   3.591(3.094-4.167)   \<0.001
  Multifocality        No                                                   ref                                                       ref                              ref                               ref                  
                       Yes                                                  0.976(0.837-1.139)                  0.760                 0.871(0.731-1.038)     0.122     0.893(0.827-0.964)      0.014     0.968(0.890-1.053)   0.454
  Extension            No                                                   ref                                                       ref                              ref                               ref                  
                       Yes                                                  13.542(11.516-15.924)               \<0.001               1.607(0.120-2.306)     0.010     2.783(2.583-2.998)      \<0.001   1.177(0.985-1.408)   0.073
  Radiation            None or refused                                      ref                                                       ref                              ref                               ref                  
                       Radiation Beam or Rdioactive implants                16.161(13.561-19.261)               \<0.001               2.223(1.734-2.851)     \<0.001   4.318(3.817-4.884)      \<0.001   1.222(1.041-1.461)   0.015
                       Radioisotopes or Radiation beam+ isotopes/implants   0.901(0.769-1.055)                  0.195                 0.738(0.603-0.904)     0.003     0.599(0.555-0.646)      \<0.001   0.670(0.611-0.735)   \<0.001
  Surgery              Biopsy                                               ref                                                       ref                              ref                               ref                  
                       Lobectomy                                            0.036(0.027-0.048)                  \<0.001               0.491(0.331-0.728)     \<0.001   0.091(0.080-0.103)      \<0.001   0.315(0.266-0.372)   \<0.001
                       Subtotal or near-total thyroidectomy                 0.081(0.059-0.112)                  \<0.001               0.699(0.448-1.091)     0.115     0.095(0.079-0.114)      \<0.001   0.335(0.269-0.418)   \<0.001
                       Total thyroidectomy                                  0.048(0.041-0.056)                  \<0.001               0.525(0.389-0.707)     \<0.001   0.069(0.063-0.076)      \<0.001   0.293(0.252-0.340)   \<0.001

Adjusting for patient characteristics using PSM {#s2_4}
-----------------------------------------------

The cancer-specific mortality rate of patients with OCPTC was similar to that of patients with CPTC and FTC (p = 0.694 and 0.111, respectively). The all-cause mortality rate of patients with OCPTC was also similar to patients with CPTC and FTC \[p = 0.207 and 0.543, respectively; (Figures [1A-1F](#F1){ref-type="fig"})\]. To minimize selection bias, propensity scored matching analysis was performed for age, sex, race, T/N/M stage, multifocality, extension, and radiation treatment approaches. In the survival analysis, patients with OCPTC had a better prognosis for cancer-specific mortality compared to patients with CPTC and FTC (p \<0.001 for both, Figures [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}) after PSM for age, sex, and race. After PSM for age, sex and race, T/N/M stage, multifocality, and extension, there were no significant differences in cancer-specific mortality between OCPTC and CPTC patients (p = 0.327); however, patients with OCPTC were observed to have a better cancer-specific survival than patients with FTC (p \< 0.001; Figures [3A-3B](#F3){ref-type="fig"}). After matching for all influential factors, including radiation treatment, the prognosis for patients with OCPTC was similar to that of those with CPTC, but better than that of patients with FTC (p = 0.325 and p \< 0.001, respectively; Figures [4A-4B](#F4){ref-type="fig"}). In survival analysis for all-cause mortality, OCPTC had a better prognosis compared to CPTC and FTC after matching for age, sex, and race (all p\<0.001, Figure [5A-5B](#F5){ref-type="fig"}). Similar results were obtained after matching for age, sex and race, T/N/M stage, multifocality, extension (Figure [6A-6B](#F6){ref-type="fig"}). After matching for all influential factors including radiation treatment, CPTC and FTC patients showed a poorer prognosis for all-cause mortality compared to patients with OCPTC (p \< 0.001 for all; Figures [7A-7B](#F7){ref-type="fig"}).

![Kaplan Meier curves among patients stratified by subtype for cancer-specific mortality **(A, B, C)** and all-cause mortality **(D, E, F)**.](oncotarget-08-77075-g001){#F1}

![Kaplan Meier curves of cancer-specific mortality for matched subtype pairs\
Age, sex and race matching between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g002){#F2}

![Kaplan Meier curves of cancer-specific mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matched between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g003){#F3}

![Kaplan Meier curves of cancer-specific mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension and radiation treatment matched between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g004){#F4}

![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
Age, sex and race matching between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g005){#F5}

![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matching between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g006){#F6}

![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension and radiation treatment matching between OCPTC and CPTC **(A)**, OCPTC and FTC **(B)** patients.](oncotarget-08-77075-g007){#F7}

DISCUSSION {#s3}
==========

Oxyphilic cells exhibit a characteristic phenotype, which features a finely granular eosinophilic cytoplasm and an increased number of mitochondria in the thyroid ultrastructurally \[[@R16]\]. Oxyphilic cells could be observed in both follicular and papillary carcinomas, originating from the thyroid gland. Furthermore, oxyphilic cells were also reported in non-neoplastic and neoplastic conditions of many other sites, such as salivary, parathyroid, and kidneys \[[@R16]\].

Oxyphilic cell tumors are a relatively rare histological type of differentiate thyroid carcinoma, and they are diagnosed mainly based on surgical specimens and cytology \[[@R17]\]. Negative results were obtained by previous researchers regarding whether oxyphilic cell thyroid carcinomas (OCTC) have a poorer prognosis than CPTC or FTC \[[@R18]--[@R20]\]. Kushchayeva *et al*. demonstrated that OCTC had a poorer cause-specific mortality rate than FTC, and suggested that OCTCs should be classified as distinct tumors \[[@R19]\]. Yasuhiro *et al*. also showed that almost 80% of the tumors were cytologically diagnosed as category IV or greater in the Bethesda System for Reporting Thyroid Cytopathology \[[@R17]\]. However, OCPTCs, a histological subtype of oxyphilic cell tumors, were rarely studied due to their low prevalence. Therefore, we compared the prognosis of OCPTC with that of CPTC and FTC, which are the most frequent histological types of thyroid malignancies.

In our study using the SEER database, histological subtype was not an independent factor for cancer-specific and all-cause mortality rates. Before matching risk variates, OCPTC had a prognosis similar to that of CPTC and FTC. The average age of participants with OCPTC was 52.22 years, which is greater than that of CPTC and FTC patients. According to studies, age is an independent risk factor of thyroid cancer-related deaths \[[@R13], [@R21]\]. In our study, when demographic profiles of patients were matched (Figure [2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}), patients with OCPTC had significantly higher survival compared to CPTC and FTC patients. This implies that if demographic data for OCPTC, CPTC and FTC patients were identical, OCPTC patients would have a better prognosis. Furthermore, after matching for all confounding factors, including clinicopathological features and radiation treatment, OCPTC had a prognosis similar to CPTC, but better than FTC. Surgeons have not yet established the most logical treatment for OCPTC, and our results may provide guidance for clinicians and complement the new American Thyroid Association guidelines.

Many patients with oxyphilic cells are recommended for total thyroidectomy due to the involvement of other lesions in the contralateral lobe or oncocytic neoplasms in the context of a multinodular goiter \[[@R22]\]. However, it is currently unknown whether patients with OCPTC should undergo prophylactic lymph node dissection. In this current study, only 17.5% of patients with OCPTC underwent lymph node metastasis; therefore, we do not recommend prophylactic lymph node dissection for this subgroup of patients unless positive detection of lymph node metastasis by preoperative ultrasonography.

Considerable attention has been directed towards combining morphological and genetic characteristics of thyroid tumors in recent years, and molecular studies have shed light on the role of various oncogenes in different thyroid tumor subsets \[[@R23]--[@R25]\]. Novel molecular-based management strategies, such as *RET-PTC*, *RAS*, *BRAF* (V600E), and *TERT* mutations for thyroid nodules and thyroid cancer are the most exciting developments in thyroid-cancer medicine \[[@R26]\].

Carcinomas with oxyphilic cell features typically harbor the genetic alterations associated with the predominant histotype of the lesion. For example, in the Hürthle cell variant of papillary thyroid carcinomas, there is a high prevalence of *RET-PTC* rearrangements and *BRAF* mutations \[[@R27]--[@R29]\]. Therefore, some authors suggested that oxyphilic cell tumors should be treated separately due to histopathological and molecular features \[[@R30]\]. The distinction between malignant and benign oxyphilic cell tumors represents a difficult diagnostic challenge, and these molecular tests may provide a new reference for oxyphilic cell tumor diagnosis and assist with treatment decision-making \[[@R22]\].

Our study had several limitations. Firstly, the utilized dataset lacked information regarding recurrence, which may introduce an overestimation bias when designating cancer-specific and all-cause mortality rates. In addition, we haven\'t added the time variable as a baseline factor for adjustment. Another limitation of this study is that family history, vascular invasion, and other histologic findings were not evaluated or included in our study. Furthermore, molecular markers, such as *BRAF* point mutation and *TERT* promotor point mutations, were not observed in our study or adjusted for in our analyses.

In summary, based on the results of our investigation, we unexpectedly observed that patients diagnosed with OCPTC had a similar prognosis to CPTC patients, but a better prognosis than FTC patients. Our findings may provide a helpful reference for future treatment decision-making.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

This investigation has been conducted in accordance with the ethical standards, according to the Declaration of Helsinki, and according to national and international guidelines. It has been approved by the authors' institutional review board.

Study population {#s4_2}
----------------

We investigated many patients with thyroid cancer, including CPTC, OCPTC, and FTC, from the SEER program. The SEER project is a United States population-based cancer registry that began in 1973, and is supported by both the Centers for Disease Control and Prevention and National Cancer Institute. It contains cancer data, such as the incidence, prevalence, mortality, population-based variables, and primary tumor characteristics (i.e., histological subtype), from multiple geographic regions.

Data collection and analysis {#s4_3}
----------------------------

We examined SEER data from 2004 to 2013, and selected patients who were diagnosed with CPTC, OCPTC, and FTC, as defined by a combination of ICD-O site code of C73.9 (i.e., thyroid, papillary, and/or follicular histology). The diagnosis codes included in the study were: "papillary carcinoma", "papillary adenocarcinoma", "Papillary carcinoma, oxyphilic cell", "follicular adenocarcinoma", and "papillary & follicular adenocarcinoma". The inclusion criteria included patients diagnosed with CPTC, OCPTC, and FTC; cases with diagnosed from 2004 to 2013 because from that time patients had information with unified AJCC TNM staging data.. We excluded the cases with other histological types and without follow-up information. Finally, to compare the survival rate among different histological subtypes, 66305 patients were included for analysis. The age, sex, race, T/N/M stage, multifocality, extension, and radiation treatment (i.e., none or refused, external beam radiation therapy, and radioactive I-131 ablation) were evaluated in patients with different histological subtypes.

Statistical analyses {#s4_4}
--------------------

Patients were followed-up until December 2013. Patient survival curves for thyroid cancer-specific mortality and all-cause mortality were examined by Kaplan-Meier analyses with the log-rank test. To further adjust for potential baseline confounding factors, a PSM analysis was conducted on demographic data, clinicopathological characteristics of thyroid cancer, and treatment approaches. Cox proportional hazards regression analyses were performed to estimate hazard ratios with 95% CIs and to show the magnitude of the effect of different histological subtypes on cancer-specific mortality and all-cause mortality \[[@R31]\]. All p-values were 2-sided, and p-values \<.05 were considered significant. Analyses were performed using SPSS version 23.0, Stata/SE version 12 (Stata Corp.), and GraphPad Prism version 6 (GraphPad Software Inc.).
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